Tags : blood cancer


Wugen Enters into License Agreement with Washington University for its

Shots: Wugen to get exclusive & IPR rights for CAR-T Technologies developed by Washington University The focus of the agreement is to develop and commercialize novel CAR-T therapies to treat blood cancer The novel CAR-T therapy platform including fratricide-resistant “off-the-shelf” system, targeting CD7+ T cell malignancies Click here to read full press release/ article | […]Read More